TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22250189
Drug: Topical carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical carmustine following intravenous O6-benzylguanine
Study: 22250189
Drug: Topical carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical carmustine
Study: 19291787
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (Interferon and Control)
Study: 17574311
Drug: Lyophilized formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized formulation of RTS,S/AS02A
Study: 17574311
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of RTS,S/AS02A
Study: 15614114
Drug: Azithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1 g orally)
Study: 15614114
Drug: Dual treatment
Normalized name: Meradimate/Octinoxate/Titanium Dioxide Topical application Lotion [PURPOSE DUAL TREATMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual treatment (azithromycin and benzathine penicillin)
Study: 15614114
Drug: Initial titers
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial titers < or =1:2 (all treatments)
Study: 12527500
Drug: IgM-enriched immunoglobulin
Normalized name: IgM-enriched immunoglobulins
DrugBank: Pentaglobin (DB15865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM-enriched immunoglobulin (Pentaglobin(R)) preparation (1,300 ml immunoglobulin, equivalent to 65 g protein)
Study: 12527500
Drug: Routine antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antibiotic prophylaxis plus placebo
Study: 12527500
Drug: IgM-enriched immunoglobulin
Normalized name: IgM-enriched immunoglobulins
DrugBank: Pentaglobin (DB15865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM-enriched immunoglobulin (Pentaglobin(R)) preparation
Study: 9703374
Drug: 250 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 microg potassium iodide daily for 4 months
Study: 9703374
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no iodine treatment)
Study: 2506603
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg adinazolam mesylate
Study: 2506603
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg adinazolam mesylate
Study: 2506603
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg adinazolam mesylate
Study: 31123181
Drug: Hyperfiltration (iGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfiltration (iGFR levels ≥140 ml/min per 1.73 m2)
Study: 31123181
Drug: Baseline GFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline GFR <140 ml/min per 1.73 m2
Study: 25504002
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus dexmedetomidine (10 µg)
Study: 25504002
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus clonidine (75 µg)
Study: 25504002
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus fentanyl (15.0 µg)
Study: 23831069
Drug: Bupivacaine infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine infiltration (20 mL of 0.25%)
Study: 18089864
Drug: Psychoeducation (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducation (six weekly 2-hour sessions)
Study: 15323591
Drug: Gepirone ER
Normalized name: gepirone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone ER (20 mg to 80 mg daily)
Study: 3982576
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same treatment as before)
Study: 10702886
Drug: Quinidine sulfate
Normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine sulfate 200 mg
Study: 8734724
Drug: Resistance load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance load of 5 cm H2O/L/sec
Study: 6218350
Drug: Erythromycin lauryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin lauryl sulfate (A-137) alcoholic solution, applied topically 3 times daily for 8 weeks.
Study: 6218350
Drug: Vehicle (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (control group), applied topically 3 times daily for 8 weeks.
Study: 26403160
Drug: Vaniprevir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaniprevir (300 mg twice daily) plus peginterferon alfa-2b and ribavirin for 12 weeks then peginterferon alfa-2b and ribavirin for 12 weeks
Study: 26403160
Drug: Vaniprevir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaniprevir (300 mg twice daily) plus peginterferon alfa-2b and ribavirin for 24 weeks
Study: 22516981
Drug: Individualized or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized or fixed‐dose GH treatment
Study: 12491045
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for chondrosarcomas
Study: 10636472
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg flumazenil
Study: 31073124
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 100 µg/vilanterol 25 µg (FF/VI)
Study: 26520926
Drug: NtRTI-sparing regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: NtRTI-sparing regimen (darunavir 800 mg once per day + ritonavir 100 mg once per day + raltegravir 400 mg twice per day)
Study: 26520926
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (darunavir 800 mg once per day + ritonavir 100 mg once per day + tenofovir 245 mg once per day + emtricitabine 200 mg once per day)
Study: 19801029
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin (50 U/kg, max 5,000 U)
Study: 19801029
Drug: Intra-arterial heparin
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial heparin (50 U/kg, max 5,000 U)
Study: 16891758
Drug: Daily walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily walking for 4 weeks
Study: 7901979
Drug: Electromyostimulation during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromyostimulation during follow-up treatment
Study: 7901979
Drug: Follow-up treatment
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up treatment
Study: 3425350
Drug: Enprofylline (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline (mean plasma concentration 3 mg l‐1)
Study: 3425350
Drug: Theophylline (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (mean plasma concentration 9 mg l‐1)
Study: 30219823
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (LDMTX) 5-15 mg/week
Study: 27630212
Drug: DPP-4i therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4i therapy (including sitagliptin)
Study: 23061387
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg intravenous every 12 hours)
Study: 23061387
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg intravenous every 6 hours)
Study: 23061387
Drug: Omeprazole (high-dose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (high-dose: 80 mg bolus plus 8 mg/hr infusion for 3 days, then 40 mg intravenous every 12 hours for 7 days)
Study: 21216122
Drug: Ten-cha (Rubus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten-cha (Rubus suavissimus) 400mg (3 capsules/day) for 4 weeks
Study: 21216122
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 capsules/day) for 4 weeks
Study: 19893562
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic and analgesics
Study: 16843192
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Simvastatin 20 mg + Fenofibrate 160 mg)
Study: 8267390
Drug: Adjuvant perioperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant perioperative portal infusion with Fluorouracil and Mitomycin
Study: 3512326
Drug: Acyclovir cream
Normalized name: Acyclovir Cream
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir cream applied 4 times per day for 16 weeks
Study: 3512326
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied 4 times per day for 16 weeks
Study: 28815419
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg daily for the first week, then 100 mg for the following seven weeks)
Study: 25154706
Drug: Intramuscular typhoid
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular typhoid vaccination
Study: 21252013
Drug: Autologous skeletal
Normalized name: Spongia officinalis skeleton extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous skeletal myoblast therapy
Study: 17357282
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with antibiotics
Study: 9188228
Drug: Surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical periodontal therapy
Study: 16600924
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) 50 mug/d plus 500 mg Ca/d
Study: 16600924
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 500 mg Ca/d
Study: 14750575
Drug: Prednisolone treatment
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone treatment starting at 40 mg per day, tapering over 4 months
Study: 11203411
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone (250 pg/12 hours) for 3 months
Study: 8725679
Drug: Missed dialysis
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Missed dialysis treatments
Study: 3909958
Drug: ACV-IFN combination
Normalized name: ACV tripeptide
DrugBank: ACV tripeptide (DB02025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACV-IFN combination
Study: 3909958
Drug: ACV-Placebo combination
Normalized name: ACV tripeptide
DrugBank: ACV tripeptide (DB02025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACV-Placebo combination
Study: 30702372
Drug: 6 mg·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg·kg‐1 of caffeine
Study: 30702372
Drug: 2 mg·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg·kg‐1 of caffeine
Study: 30702372
Drug: 4 mg·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg·kg‐1 of caffeine
Study: 17690882
Drug: RBC transfusion
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC transfusion to maintain Hb levels >or=10 g/dl (arm 1)
Study: 17690882
Drug: RBC transfusion
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC transfusion to maintain Hb levels >or=12 g/dl (arm 2)
Study: 10686454
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation (INR 2.0-3.0)
Study: 10686454
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dipyridamole (400 mg daily) plus aspirin (30-325 mg daily)
Study: 9495426
Drug: Tropisetron 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 0.5 mg
Study: 1387073
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy alone (control group)
Study: 19804593
Drug: 5-aminolaevulinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-aminolaevulinic acid (5-ALA) patch-PDT
Study: 22944145
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of markers
Study: 16424843
Drug: L-glutamate (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamate (n = 10)
Study: 10212170
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion (10% solution, 5 ml/kg for 30 minutes)
Study: 31124147
Drug: 6 mm
Normalized name: I-Port, 6 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mm implants alone
Study: 31124147
Drug: 8 mm
Normalized name: potassium 8 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mm implants + OSFE
Study: 31124147
Drug: 10 mm
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mm implants + OSFE
Study: 28701288
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose fentanyl (33 μg kg−1 loading dose, 0.2 μg kg−1 minute−1)
Study: 28701288
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose fentanyl (102 μg kg−1 loading dose, 0.8 μg kg−1 minute−1)
Study: 26664151
Drug: L-carnitine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine 600 mg oral daily
Study: 21668522
Drug: Micafungin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (100 mg day(-1) for adults; 2 mg kg(-1) day(-1) for children)
Study: 21668522
Drug: Micafungin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (100 or 150 mg day(-1))
Study: 21668522
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (L-AmB 3 mg kg(-1) day(-1))
Study: 21668522
Drug: Caspofungin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (50 mg day(-1); 70 mg loading dose)
Study: 21668522
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs (Micafungin, L-AmB, Caspofungin)
Study: 18295615
Drug: Twelve‐week adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twelve‐week adherence intervention (weekly phone calls and home visit) including counseling on establishing, monitoring, and problem‐solving in maintaining a home exercise program
Study: 16932345
Drug: Non-infusional consolidation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-infusional consolidation chemotherapy (mini-ICE regimen)
Study: 16932345
Drug: Intravenous consolidation
Normalized name: BAG,LEG LARGE CONSOLIDATED #0932
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous consolidation chemotherapy (mini-ICE regimen)
Study: 16932345
Drug: Both non-infusional
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both non-infusional and intravenous consolidation chemotherapy
Study: 9334893
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg daily for 20 weeks)
Study: 9334893
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after withdrawal from fluoxetine)
Study: 2930987
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg cyproterone acetate (CA) + Diane (2 mg CA + 50 micrograms ethinyloestradiol) for 9 months
Study: 2930987
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg cyproterone acetate (CA) + Diane (2 mg CA + 50 micrograms ethinyloestradiol)
Study: 2930987
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Diane (2 mg CA + 50 micrograms ethinyloestradiol)
Study: 2930987
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose CA
Study: 26481764
Drug: Kidney injury
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kidney injury molecule‐1 (KIM‐1) measured 24 h after operation
Study: 24682986
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with 0.1% ropivacaine+0.1 μg/mL sufentanil (for postoperative 48 h)+injected pethidine on demand
Study: 24682986
Drug: Oral analgesia
Normalized name: P-A-C Analgesic Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesia with controlled-release oxycodone (2x15 mg for the first postoperative 24 h; 2x10 mg for the second postoperative 24 h)+paracetamol and tramadol hydrochloride tablets (8x1 tablet for the postoperative 48 h) orally+injected pethidine on demand
Study: 12097688
Drug: Zinc-restricted diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc-restricted diet (4.6 mg/d) during the 10-week zinc-restriction (ZR) period
Study: 12097688
Drug: Zinc supplements
Normalized name: Zinc Supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplements (9.1 mg/d) during the 5-week baseline (BL) and 5-week repletion (RP) periods
Study: 10424318
Drug: digoxin 0.25
Normalized name: digoxin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: digoxin 0.25 mg twice daily
Study: 7548447
Drug: Se-rich bread
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se-rich bread with 100, 200, and 300 micrograms Se daily for 6 weeks
Study: 7548447
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms selenomethionine daily for 15 weeks
Study: 6998594
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of the live oral typhoid vaccine Ty21a (1 x 10(9)‐8 x 10(9) live bacteria)
Study: 20684724
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of placebo
Study: 29143869
Drug: MDMA 75
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 75 mg with Ketanserin 40 mg
Study: 20639792
Drug: Preterm formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preterm formula containing 0.8 g/100 mL short‐chain galacto‐oligosaccharides/long‐chain fructo‐oligosaccharides in a 9:1 ratio
Study: 11887119
Drug: Mailed physician
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mailed physician reminders (4 monthly reminders)
Study: 3359804
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 110 mg retinyl palmitate (vitamin A supplementation)
Study: 18418239
Drug: Adjunctive balloon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive balloon postdilation (ABP)
Study: 18418239
Drug: No adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjunctive balloon postdilation (no ABP)
Study: 3514363
Drug: metronidazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: metronidazole (200 mg)
Study: 3401284
Drug: Bezafibrate (BZF)
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (BZF) 400-600 mg/day for 15-30 days
Study: 3401284
Drug: Bezafibrate (BZF)
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (BZF) 400 mg/day for 15 days
Study: 30838669
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training based on physical activity recommendation from WHO (PAR group)
Study: 29165355
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (HI-NI; 140 mL containing 12.9 mmol nitrate)
Study: 25862491
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle training (PFMT) program, 12 group sessions, twice a week, 30 min each.
Study: 24304733
Drug: Oral methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methionine load (OML) test
Study: 16983180
Drug: Methimazole treatment
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole treatment for 2 years
Study: 27288475
Drug: Vilaprisan (VPR)
Normalized name: Vpriv
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan (VPR) 0.1 mg
Study: 27288475
Drug: Vilaprisan (VPR)
Normalized name: Vpriv
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan (VPR) 0.5 mg
Study: 27288475
Drug: Vilaprisan (VPR)
Normalized name: Vpriv
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan (VPR) 1 mg
Study: 27288475
Drug: Vilaprisan (VPR)
Normalized name: Vpriv
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan (VPR) 2 mg
Study: 27288475
Drug: Vilaprisan (VPR)
Normalized name: Vpriv
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan (VPR) 5 mg
Study: 23546172
Drug: Pemetrexed 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 600 mg/m², D1 i.v. q21; Carboplatin, AUC 5, D1 i.v. q21 (Arm A)
Study: 23546172
Drug: Gemcitabine 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,200 mg/m² D1, D8 i.v. q21; Vinorelbine 30 mg/m² D1, D8 i.v. q21 (Arm B)
Study: 21219813
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin at 2 IU/ml
Study: 16860852
Drug: 6 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of carboplatin (7.5 AUC over 30 min) and paclitaxel (175 mg/m2 over 3 h) every 21 days
Study: 16860852
Drug: 3 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of carboplatin (7.5 AUC over 30 min) and paclitaxel (175 mg/m2 over 3 h) every 21 days
Study: 12930333
Drug: Purpura-free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purpura-free treatment with pulsed-dye laser
Study: 12930333
Drug: Purpura treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purpura treatment with pulsed-dye laser
Study: 12930333
Drug: Purpura-free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purpura-free treatment with pulsed-dye laser (fewer than 250 pulses)
Study: 12930333
Drug: Purpura-free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purpura-free treatment with pulsed-dye laser (greater than 250 pulses)